Skip to main content
. 2001 Apr 17;98(9):5049–5054. doi: 10.1073/pnas.081547998

Figure 2.

Figure 2

XIAP inhibits general apoptotic triggers, in vitro. (A) Thymocytes from lckpr-xiap lines 1 (n = 16, P < 0.01) and 2 (n = 12, P < 0.01), and wild-type thymocytes (5 × 106 cells/ml) were exposed to C2 ceramide (10 μM) for the time periods indicated. (B) Lckpr-xiap line 1 and wild-type thymocytes (5 × 106 cells/ml) were exposed to UV radiation (1,000 μJ/cm2) (n = 8, P < 0.01) for the time periods indicated. (C) Lckpr-xiap line 1 and wild-type thymocytes (5 × 106 cells/ml) were treated with either anti-Fas antibody (Jo2, 5 μg/ml) in combination with cycloheximide (30 μg/ml) (n = 24, P < 0.01), with cycloheximide (30 μg/ml) alone, or with anti-Fas (n = 24, P < 0.01) alone for 12 h. (D) Lckpr-xiap line 1 and wild-type thymocytes (5 × 106 cells/ml) were treated with either mouse Fas antibody (5 μg/ml) (n = 20, P < 0.01) or human specific anti-Fas antibody (5 μg/ml) (n = 20, P < 0.01) for 18 h. All mice used were between 4 and 5 weeks old.